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Abstract
The source tissue for biomarkers mRNA expression profiling of tumors has traditionally been fresh-frozen tissue. The
adaptation of formalin-fixed, paraffin-embedded (FFPE) tissues for routine mRNA profiling would however be invaluable in
view of their abundance and the clinical information related to them. However, their use in the clinic remains a challenge
due to the poor quality of RNA extracted from such tissues. Here, we developed a method for the selection of melanoma
archival paraffin-embedded tissues that can be reliably used for transcript biomarker profiling. For that, we used qRT-PCR to
conduct a comparative study in matched pairs of frozen and FFPE melanoma tissues of the expression of 25 genes involved
in angiogenesis/tumor invasion and 15 housekeeping genes. A classification method was developed that can select the
samples with a good frozen/FFPE correlation and identify those that should be discarded on the basis of paraffin data for
four reference genes only. We propose therefore a simple and inexpensive assay which improves reliability of mRNA
profiling in FFPE samples by allowing the identification and analysis of ‘‘good’’ samples only. This assay which can be
extended to other genes would however need validation at the clinical level and on independent tumor series.
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Introduction
Malignant melanoma is one of the most rapidly spreading
cancers in terms of worldwide incidence [1]. The lack of
prognostic markers or efficient treatments of advanced melanoma
represents a major problem in patient management [2,3].
Melanoma personalized medicine is promising but requires the
discovery and application of clear prognostic and predictive
biomarkers to guide therapeutic decisions [4]. The gold standard
of source tissue for biomarkers mRNA expression profiling has
traditionally been fresh-frozen tissue which can be feasible and
informative in the evaluation of gene transcripts. However,
formalin-fixed paraffin-embedded tissue (FFPE) represents by far
the most abundant supply of melanoma tumors and as a rule the
sole material available for primary tumors [5,6]. Indeed, with the
enormous amount of data retrievable stored in archived forma-
lin-fixed paraffin-embedded tissue, it will prove invaluable if
biomarkers transcript expression levels could be routinely and
systematically analyzed in FFPE tissues, particularly for retrospec-
tive studies and for the characterization of rare or small tumors.
However, their routine use in the clinic has been hampered because
of the poor quality of RNA extracted from them. However, a few
emerging studies using qRT-PCR as well as microarrays suggested
these FFPE samples can be used to validate biomarker signatures
associated with clinical features, survival and therapeutic response
[7,8,9,10,11,12]. These studies, conducted mainly in breast cancer
tissues have shown a strong correlation in transcript expression
between paired FFPE and frozen tissues which was independent of
tissue fixation time and storage in paraffin.
Despite a wealth of data, the most useful prognostic indicators of
primary melanoma remain Breslow depth, presence or absence of
ulceration, mitotic index for thin tumors and lymph node
involvement. Recently, the prognostic value of BRAF and NRAS
mutation was demonstrated in several retrospective studies [13,14]
and [Jakob J et al., ASCO 2011]. The importance of targeting this
pathway for melanoma treatment has been demonstrated in vitro,
in pre-clinical animal models and more recently in recent clinical
trials [15,16,17]. However the observed response in these trials
seems to be transient and only for the 50% of melanoma mutated
in BRAF, underlining the need for searching new relevant targets
in [18,19]. In a recent multiparametric study deciphering tumor
angiogenesis and invasion in melanoma, we demonstrated that the
expression of VEGF 121 and PAI1 was significantly associated
with the presence of a micrometastasis in the sentinel lymph node
[20] and [Mourah et al, AACR 2007] highlighting the prognostic
potential of the genes expressed in these biological pathways.
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collections, we conducted a comparative study using qRT-PCR on
a wider biomarkers gene panel involved in angiogenesis/tumor
invasion in matched pairs of frozen and FFPE melanoma tissues. A
statistical method was developed that can select the samples with
good correlations and identify those that should be discarded on
the basis of the paraffin data only.
Results
Comparison of RNA Expression Profiles from FFPE and Fresh
Frozen Melanoma Tissues: The expression in malignant melano-
ma of 25 genes involved in angiogenesis, lymphangiogenesis and
tumor invasion pathways was analyzed. For that, total RNA was
prepared from 25 matched pairs of frozen and FFPE samples.
Inspection of RNA by Agilent Bioanalyzer electrophoresis
demonstrated a typical non degraded RNA profile in the frozen
specimens while FFPE extracts displayed degraded RNA around
150 and 50 bp, depending on the samples (Fig. 1a). These
observations are consistent with previous studies which described
similar profiles for FFPE.
Heterogeneityinthequalityand quantity ofthe RNAextractedis
known to be mainlydueto variations intissuequantity,fixation type
and to the delay in tissue fixation after surgery. Furthermore, the
efficiency of the reverse transcription and the PCR itself may
represent an added variability parameter. In view of this, the
qRT-PCR measurements of the genes of interest were normalized
to a validated set of housekeeping genes. This validated set was
determined by comparing 15 different housekeeping genes between
frozen and FFPE matched tissues, out of which 10 genes showing
stable expression (very close means between FFPE and frozen
specimens) were retained as reference housekeeping gene set.
Fig. 1b represents a Boxplot of mean mRNA levels of 19 genes
of interest and 10 housekeeping genes in all frozen and FFPE
samples showing comparable means for most but not all genes. As
example, VEGFR-2 and PDGFR-beta show closely matched
means while MMP1 and PDGFR-alpha were unmatched.
A correlation frozen/FFPE on the median of each gene was
evaluated on all patients, yielding a very good Person correlation
coefficient of 0.88, p,0.0001, as presented in Fig. 2a.
The same correlation was determined individually for each
patient and examples of patients with good, average and bad frozen/
FFPE correlation is shown in Fig. 2b and 2c (Person correlation
coefficient of 0.87 and 0.48, p,0.0001 and p=0.007 respectively).
After Bonferroni adjustment for multiple-testing, we have
chosen as ‘good’ the samples with an adjusted p-value below the
5% level and as ‘bad’ those with an adjusted p-value above 10%
level. Remaining samples with adjusted p-values between 5% and
10% were considered as ‘average’. Out of the 25 samples analysed,
we obtained 21 good, one average and 3 bad samples (Fig. 3) (see
Table S1).
Figure 1. RNA analyses. a. Representative total RNA integrity analysis paired frozen and FFPE tissue specimens using Capillary electrophoresis
Agilent 2100 bioanalyzer, shows that in the FFPE samples RNA exists primarily as fragments between 200 and 100 bases in length. Left panel: fresh
frozen human melanoma tissue. Right panel: matched FFPE tissue. b. Boxplot represents the mean mRNA levels and gene expression between frozen
and FFPE samples. In red, reference genes.
doi:10.1371/journal.pone.0029143.g001
A Reliable Method to Exploit Melanoma FFPE Tissues
PLoS ONE | www.plosone.org 2 January 2012 | Volume 7 | Issue 1 | e29143Identification of samples with a good gene expression
correlation between frozen and FFPE: We next aimed to develop
a simple statistical method that can identify melanoma samples
with a good correlation frozen/FFPE and so to discard samples for
which expression levels do not correlate, on the basis of paraffin
data for reference genes only.
This approach was based on the assumption that the expression
level for these reference genes should remain globally stable across
good samples. To this end, we defined ‘Mean-Good-Expression-
Profile’ (MGEP) as the mean of individual good samples
expression profiles and those samples deviating significantly from
the MGEP as bad sample profiles. Deviation was measured and
tested with a classical chi-square test. This approach is fully
described in Figure S1, and a R script is available on demand.
Among the 21 good samples identified, 14 were used as training
samples to construct the MGEP (selected based on a correlation p-
value below 10
23). The 7 remaining good samples and the 3 bad
samples were used for validation.
Of all the possible sets of reference genes available to construct
the MGEP, we chose the set with the minimum mean coefficient
of variation on the training samples which corresponds to four
genes: Actine, HPRT, TBP and TRFC. With this set of reference
genes, our MGEP-based approach discriminated perfectly the
21 good from the 3 bad samples (100% of good prediction). The
remaining average sample was identified as good.
Discussion
FFPE tumor samples represent a great potential for gene
expression profiling. However, their use was so far limited by the
poor quality of RNA extracted from such tissues which reduces the
reliability of biomarker quantification [21]. This study was
conducted on melanoma lesions comparing frozen and FFPE
extracts for a panel of 25 genes involved in angiogenesis and
invasion. Data analysis revealed that in spite of the degraded RNA
in the FFPE samples, only a small proportion of extracts could
not be exploited. We therefore propose herein a simple and
inexpensive assay which specifically identifies this subgroup which
may be discarded thus allowing the selection of exploitable FFPE
samples. The fact that this proposed assay is based on the
assessment of only 4 reference genes to select ‘‘good’’ melanoma
archived samples renders it suitable for clinical use.
Our results show a very good Pearson CC of 0.88, higher than
previously reported in the few studies attempting to show the
reliability of FFPE RNA extracts in matched FFPE/frozen tissues
which at best yielded values between 0.7–0.8 in various tumor types
[6,21,22]. Several factors may have contributed to the higher
Person values obtained in our study i) all samples were mono-
centrically collected and thus variations due to delay in tissue
fixation after surgery as well as fixation time were minimal; ii) all
analysed sample blocks were checked by a pathologist to contain at
least90% oftumorcells;iii)transcript quantification used amplicons
smaller than 100 bp (between 60 and 80 bp) which allows the
amplificationofgreaternumberofgenesinthedegradedspecimens.
The high FFPE/Frozen correlation obtained when considering
the whole studied melanoma samples nevertheless contained
several samples (3/24) with bad correlation (0.4), prompting us to
Figure 2. Frozen/FFPE correlations. a. Correlation in all the patients
and for all the genes between the two tissue preparation methods. The
adjusted Pearson correlation between FFPE and frozen tissue for all
tested genes was greater (Pearson coefficient=0.88 p,0,0001). b. Two
examples of correlations determined individually for each patient
measured in all genes.
doi:10.1371/journal.pone.0029143.g002
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and so improve reliability of mRNA profiling in FFPE samples.
The method described here can therefore contribute to improve
validity of prognostic or predictive biomarkers in clinical work.
Cronin et al previously validated both analytically and clinically
a FFPE molecular biomarker tests in breast cancer patients
predicting survival and therapeutic response [8]. With this method
using amplicons of approximately 100 bp for transcript quantifi-
cation, a 16 gene signature was shown to be enough to predict
response to Tamoxifen genes [11]. Our results presented here
suggest that discarding individual bad samples in these studies may
have further improved the predictive value of transcript biomark-
ers to response to treatment.
Since the validation of our test is required before it can be
recommended for routine use in evaluating prognostic markers in
FFPE samples, this pilot study is currently extended to include
large cohorts, such as the melancohort already available for the
Great Paris area [23]. In addition, this new test could be suitable
for identifying new biomarkers involved in other molecular
pathways regulating melanoma progression, the inclusion of which
will undoubtedly improve the prognostic value of the test.
Materials and Methods
Patients
From 2000 to 2005, formalin-fixed and paraffin-embedded
(FFPE) tissue specimens or frozen for the same tumor sections
were available for 25 patients referred to our department with
primary melanoma n=7, cutaneous metastasis n=4, lymph node
metastasis n=14. The study was performed in accordance with
the precepts established by the Helsinki Declaration and approved
by the Hopital Saint Louis Research Ethic Committee (Paris,
France). All patients gave informed written consent.
Samples, RNA extraction and reverse transcription
All tissues were collected according to the guidelines and policies
of Saint Louis Hospital – University of Paris 7 Institutional Board.
Freshfrozenmelanomatissuesweredividedandhalfkeptfrozenand
half fixed in formalin and processed for paraffin embedded. Over
90% of the tissue is composed of tumor cells. Five and ten 10 mm
sections for frozen tissue for FFPE block respectively were obtained
for the RNA extraction. The total RNA of the 25 pairs of archival
melanoma tumor FFPE blocks and matching frozen tumors were
extracted with the Chomcynsky and Sacchi method [24] for the
frozen specimens and using Qiagen RNA FFPE extraction kit after
xylene traitment for FFPE specimens (10 sections of 10 mm)
according to the manufacturer’s protocol. Each sample was treated
with DNase I, to eliminate any traces of genomic DNA. Reverse
transcription was performed using Super-Script II (Invitrogen).
FFPE tissue RNA analysis and taqMan primer and probe design.
The total RNA yield was determined using a NanoDrop ND-
1000 spectrophotometer (NanoDrop Tech, Wilmington, DE). RNA
integrity was assessed by Agilent 2100 Bioanalyzer electrophoresis
(Agilent Technologies) compared to standard reference RNA as
previously described [8].
RT-PCR probes and primers were designed, tested and validated
in our laboratory. Amplicon sizes were preferably limited to less
than 200 pb in length. Fluorogenic probes were dual-labelled with
5-FAM as a reporter and TAMRA as a quencher.
Multiparametric transcripts quantification
The studied angiogenesis/lymphangiogenesis and
invasion biomarkers were VEGFs (solubles forms VEGF121
and VEGF165), VEGF recepteurs (VEGFR1 and VEGFR2),
PDGF-A, PDGF-B, PDGF receptors (PDGFR-alpha and –beta),
Serine proteases (uPA PAI-1) and Matrix Metalloproteinase
Figure 3. Corrected FFPE/Frozen correlations for each individual. The correlation test tries the hypothesis «the correlation is useless’’. The
threshold represents the threshold reject alpha=5% (correct for the multiple test by Bonferroni). The individuals to spread are the ones who are
below the threshold.
doi:10.1371/journal.pone.0029143.g003
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inducer EMMPRIN, regulators transcription factors of angio/
lymphangio: HIF1a, PROX-1. The studied reference tran-
scripts were TBP, B2 microglobin, GAPDH, ACTBP, GUS,
PPIA, TFRC, 18S, 5S, RPLP1, RPLP0, RPL5, RPL19, Actin-
alpha and beta-actin.
TaqMan reactions were performed to quantify the multi-
parametric transcripts. The quantification was using the PerfectP-
robe Master Mix kit (AnyGenes, France) on a LightCycler 2.0. All
the experiements were measured in duplicate. PCR cycling was
performed as follows: 95uC for 10 minutes for one cycle, 95uC for
20 secondes, and 60uC for 45 secondes, for 40 cycles.
Normalization
To compare expression profiles between specimens, normaliza-
tion based on 15 reference genes was used to correct for
differences arising from variability in RNA quality and total
quantity of RNA in each assay. 10 reference genes were selected
for use from among 15 candidate reference genes tested in this
assay. The relative quantification of each transcript was referred to
the Cronin work [8].
Statistical Analysis
The statistical analyses described in the section «Results» was
assayed with the software R
1 (version 2.13.1). P-values are
considered significant below the 5% level after Bonferroni
adjustment for multiple-testing.
Supporting Information
Figure S1 Classification approach: supplementary method
defining the ‘Mean-Good-Expression-Profile’ (MGEP) as the
mean of individual good samples expression profiles and those
samples deviating significantly from the MGEP as bad sample
profiles. Deviation was measured and tested with a classical chi-
square test.
(PDF)
Table S1 Sample correlations and quality.
(XLS)
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